Ambroxol inhibits neutrophil respiratory burst activated by alpha chain integrin adhesion

Int J Immunopathol Pharmacol. 2013 Oct-Dec;26(4):883-7. doi: 10.1177/039463201302600406.

Abstract

The purpose of the present study was to investigate the possible anti-oxidant effect(s) of Ambroxol on neutrophils activated by ligand-binding of the drug with membrane-associated adhesion integrin CD11a and to estimate dose-response changes in oxygen free radical production. The amount of free radical production by anti-CD11a- and anti-CD4-coated neutrophils stimulated with N-formyl-methionyl-leucyl-phenylalanine (FMLP) and challenged with increasing concentration of Ambroxol, was evaluated within a time frame of 90 minutes. A significant dose-dependent effect response of Ambroxol on O2‾ production by cells coated with anti-CD11a antibody was observed. This preliminary study opens a new perspective on the therapeutic role of Ambroxol as an antioxidant drug and for its potential use in controlling oxidative stress, particularly in leukocyte-dependent inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ambroxol / pharmacology*
  • Antioxidants / pharmacology*
  • CD11a Antigen / physiology*
  • Calcium / metabolism
  • Cell Adhesion
  • Dose-Response Relationship, Drug
  • Humans
  • Neutrophils / drug effects*
  • Neutrophils / metabolism
  • Respiratory Burst / drug effects*

Substances

  • Antioxidants
  • CD11a Antigen
  • Ambroxol
  • Calcium